|
Clinical Trials and Observations
Citations 51-60 of 2742 total displayed.
|
Past content
(since May 1998):
|
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features
- Claudia Haferlach, Cristina Mecucci, Susanne Schnittger, Alexander Kohlmann, Marco Mancini, Antonio Cuneo, Nicoletta Testoni, Giovanna Rege-Cambrin, Antonella Santucci, Marco Vignetti, Paola Fazi, Maria Paola Martelli, Torsten Haferlach, and Brunangelo Falini
Blood 2009; 114: 3024-3032.
[Abstract]
[Full text]
[PDF]
Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment
- Mikkael A. Sekeres and David P. Steensma
Blood 2009; 114: 2575-2580.
[Abstract]
[Full text]
[PDF]
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
- Thorsten Zenz, Sonja Häbe, Tina Denzel, Julia Mohr, Dirk Winkler, Andreas Bühler, Antonio Sarno, Silja Groner, Daniel Mertens, Raymonde Busch, Michael Hallek, Hartmut Döhner, and Stephan Stilgenbauer
Blood 2009; 114: 2589-2597.
[Abstract]
[Full text]
[PDF]
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib
- Richard D. Press, Stephanie G. Willis, Jennifer Laudadio, Michael J. Mauro, and Michael W. N. Deininger
Blood 2009; 114: 2598-2605.
[Abstract]
[Full text]
[PDF]
Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose
- Michael A. Pulsipher, Pintip Chitphakdithai, Brent R. Logan, Susan F. Leitman, Paolo Anderlini, John P. Klein, Mary M. Horowitz, John P. Miller, Roberta J. King, and Dennis L. Confer
Blood 2009; 114: 2606-2616.
[Abstract]
[Full text]
[PDF]
The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
- Cheng E. Chee, Shaji Kumar, Dirk R. Larson, Robert A. Kyle, Angela Dispenzieri, Morie A. Gertz, Colin L. Colby, and S. Vincent Rajkumar
Blood 2009; 114: 2617-2618.
[Abstract]
[Full text]
[PDF]
Restoration of NET formation by gene therapy in CGD controls aspergillosis
- Matteo Bianchi, Abdul Hakkim, Volker Brinkmann, Ulrich Siler, Reinhard A. Seger, Arturo Zychlinsky, and Janine Reichenbach
Blood 2009; 114: 2619-2622.
[Abstract]
[Full text]
[PDF]
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma
- Mark P. Purdue, Qing Lan, Otoniel Martinez-Maza, Martin M. Oken, William Hocking, Wen-Yi Huang, Dalsu Baris, Betty Conde, and Nathaniel Rothman
Blood 2009; 114: 2730-2732.
[Abstract]
[Full text]
[PDF]
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
- Tamer E. Fandy, James G. Herman, Patrick Kerns, Anchalee Jiemjit, Elizabeth A. Sugar, Si-Ho Choi, Allen S. Yang, Timothy Aucott, Tianna Dauses, Rosalie Odchimar-Reissig, Jonathan Licht, Melanie J. McConnell, Chris Nasrallah, Marianne K. H. Kim, Weijia Zhang, Yezou Sun, Anthony Murgo, Igor Espinoza-Delgado, Katharine Oteiza, Ibitayo Owoeye, Lewis R. Silverman, Steven D. Gore, and Hetty E. Carraway
Blood 2009; 114: 2764-2773.
[Abstract]
[Full text]
[PDF]
How I treat Waldenström macroglobulinemia
- Steven P. Treon
Blood 2009; 114: 2375-2385.
[Abstract]
[Full text]
[PDF]
|
|
